1
|
Klymenko T, Kononovych M. Clinical significance of correlation between persistent pulmonary hypertension and 8-hydroxy-2-desoxyguanosine level in premature newborns. J Neonatal Perinatal Med 2022; 16:81-85. [PMID: 36530094 DOI: 10.3233/npm-221005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND: Persistent pulmonary hypertension is a problem that leads to high morbidity and mortality in preterm infants. In clinical studies, oxidative stress (OS) contributes to the development of pulmonary hypertension (PH). The most specific biomarker of OS in preterm infants is urinary 8-hydroxy-2-deoxyguanosine (8-OHdG). The aim of the study was to determine the clinical correlation between the value of 8-OHdG and the level of a mean pressure in the pulmonary artery (mPAP) in premature infants with respiratory distress syndrome (RDS) and asphyxia in the early neonatal period. METHODS: Determination of the urinary 8-OHdG value and PH in 96 premature infants born at gestational age of 26–32 weeks on the 1st and the 3rd–5th days of life in two groups: group I –52 children with respiratory distress syndrome; II –44 children with RDS associated with perinatal asphyxia. RESULTS: The 2nd group of children had higher average mPAP level, mmHg, both in the 1st and in the 3rd–5th day of life compared with the 1st group. The value of the urinary 8-OHdG correlated with the manifestation of PH that required prolonged respiratory support in group II. CONCLUSION: Perinatal asphyxia in preterm infants with RDS on the 1st day of life complicates the course of PH, as indicated by a higher level of the urinary 8-OHdG and correlated to mPAP. Gender characteristics of the dynamics of 8-OHdG levels in children with perinatal pathology reveal reduced adaptability and reactivity of boys to OS at birth.
Collapse
Affiliation(s)
- T.M. Klymenko
- Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine
| | - M.I. Kononovych
- Municipal Non-Profit Enterprise City Perinatal Center of Kharkiv city, Kharkiv, Ukraine
| |
Collapse
|
2
|
Huang W, Liu N, Tong X, Du Y. Sildenafil protects against pulmonary hypertension induced by hypoxia in neonatal rats via activation of PPARγ‑mediated downregulation of TRPC. Int J Mol Med 2022; 49:19. [PMID: 34935055 PMCID: PMC8722768 DOI: 10.3892/ijmm.2021.5074] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Accepted: 11/04/2021] [Indexed: 11/06/2022] Open
Abstract
Persistent pulmonary hypertension of the newborn (PPHN) is a common pulmonary vascular disease during the neonatal period, and it is associated with a high clinical mortality rate and a poor prognosis. At present, the treatment of PPHN is based mainly on inhaled nitric oxide (iNO), high‑frequency ventilation, and pulmonary vasodilators. Sildenafil has gradually begun to be used in recent years for the treatment of PPHN and has exhibited some success; however, its detailed mechanism of action requires further elucidation. An animal model of neonatal pulmonary hypertension (neonatal rats, 48 h after birth, 10% O2, 14 days) as well as a cell model [human pulmonary artery smooth muscle cells (PASMCs), 4% O2, 60 h] were established. The effects of sildenafil on pulmonary hypertension in neonatal rats were evaluated by hematoxylin and eosin staining, immunofluorescence analysis, western blotting and PCR, and the changes in peroxisome proliferator‑activated receptor γ (PPARγ), transient receptor potential canonical (TRPC)1, TRPC6 and Ki67 expression levels were detected under hypoxic conditions. The results revealed that sildenafil reversed the increases in the right ventricular mean pressure and right ventricular hypertrophy index induced by hypoxia, and attenuated pulmonary arterial remodeling as well as PASMC proliferation. The inhibitory effects of sildenafil on TRPC expression and PASMC proliferation were attenuated by GW9662 and PPARγ small interfering RNA. In conclusion, sildenafil protects against hypoxia‑induced pulmonary hypertension and right ventricular hypertrophy in neonatal rats by upregulating PPARγ expression and downregulating TRPC1 and TRPC6 expression.
Collapse
Affiliation(s)
- Wanjie Huang
- Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
| | - Na Liu
- Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
| | - Xin Tong
- Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
| | - Yanna Du
- Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
| |
Collapse
|
3
|
Luo F, Wu L, Xie G, Gao F, Zhang Z, Chen G, Liu Z, Zha L, Zhang G, Sun Y, Zhang Z, Wang Y. Dual-Functional MN-08 Attenuated Pulmonary Arterial Hypertension Through Vasodilation and Inhibition of Pulmonary Arterial Remodeling. Hypertension 2021; 77:1787-1798. [PMID: 33775126 DOI: 10.1161/hypertensionaha.120.15994] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Fangcheng Luo
- From the Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan University and Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (F.L., L.W.)
| | - Liangmiao Wu
- From the Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan University and Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (F.L., L.W.)
| | - Guoqing Xie
- Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (G.X., F.G., Zhixiang Zhang, G.C., L.Z., G.Z., Y.S., Zaijun Zhang, Y.W.)
| | - FangFang Gao
- Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (G.X., F.G., Zhixiang Zhang, G.C., L.Z., G.Z., Y.S., Zaijun Zhang, Y.W.)
| | - Zhixiang Zhang
- Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (G.X., F.G., Zhixiang Zhang, G.C., L.Z., G.Z., Y.S., Zaijun Zhang, Y.W.)
| | - Guangying Chen
- Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (G.X., F.G., Zhixiang Zhang, G.C., L.Z., G.Z., Y.S., Zaijun Zhang, Y.W.)
| | - Zheng Liu
- School of Stomatology and Medicine, Foshan University, P. R. China (Z.L.)
| | - Ling Zha
- Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (G.X., F.G., Zhixiang Zhang, G.C., L.Z., G.Z., Y.S., Zaijun Zhang, Y.W.)
| | - Gaoxiao Zhang
- Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (G.X., F.G., Zhixiang Zhang, G.C., L.Z., G.Z., Y.S., Zaijun Zhang, Y.W.)
| | - Yewei Sun
- Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (G.X., F.G., Zhixiang Zhang, G.C., L.Z., G.Z., Y.S., Zaijun Zhang, Y.W.)
| | - Zaijun Zhang
- Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (G.X., F.G., Zhixiang Zhang, G.C., L.Z., G.Z., Y.S., Zaijun Zhang, Y.W.)
| | - Yuqiang Wang
- Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, China (G.X., F.G., Zhixiang Zhang, G.C., L.Z., G.Z., Y.S., Zaijun Zhang, Y.W.)
| |
Collapse
|